M.B.X. Biosciences (MBX)
Develops precision peptide therapies for endocrine and metabolic disorders.
Something off on this page? Send us feedback.
Develops precision peptide therapies for endocrine and metabolic disorders through a clinical-stage pipeline. The portfolio centers on canvuparatide for chronic hypoparathyroidism, obesity candidates including MBX 4291 and MBX 5765, and imapextide for post-bariatric hypoglycemia, with no approved products or product-sales revenue.
Develops precision peptide therapies for endocrine and metabolic disorders from a single reportable segment. The pipeline is clinical and preclinical rather than commercial, with canvuparatide as the most advanced program for chronic hypoparathyroidism.
Obesity work includes MBX 4291, a GLP-1/GIP co-agonist prodrug in clinical evaluation, and MBX 5765, an amycretin prodrug candidate moving through enabling studies. Imapextide adds a program for post-bariatric hypoglycemia.
Based in Carmel, Indiana, the company has no approved products or product-sales revenue. Its business depends on trial execution, regulatory clearance, intellectual-property protection, and continued financing before any marketed therapy can generate revenue.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | Truist Financial | Target | Target: $70 | Target: $88 |
| Aug 7, 2026 | Barclays | Reiterate | Rating: —Target: $70 | Target: $88 |
| Jul 23, 2026 | UBS | Reiterate | Rating: —Target: $60 | Target: $90 |
| May 12, 2026 | Stifel Nicolaus | Target | Target: $50 | Target: $56 |
| May 12, 2026 | Barclays | Reiterate | Rating: —Target: $66 | Target: $70 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $418.6M · Total debt $3.3M · Total assets $435.9M · Shareholders' equity $409.5M
- Revenue
- $0
- Operating income
- −$40.9M
- Net income
- −$37.1M
No dividends on record.
| Institutions | ≈ 115.35% | 55.55M shares | |
|---|---|---|---|
| 182 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.91% | 1.40M shares | |
| 6 holders · as of Aug 5, 2026 | |||
| Adds to | 118.26% | ||
48.16M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 118.26%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Frazier Life Sciences Management, L.P.Institution | 13.81% | 6.65M | as of Jun 30, 2026 |
FMR LLCInstitution | 11.05% | 5.32M | as of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 10.34% | 4.98M | as of Jun 30, 2026 |
Nea Management Company, LLCInstitution | 7.51% | 3.61M | as of Jun 30, 2026 |
Orbimed Advisors LLCInstitution | 7.12% | 3.43M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Salomon Azoulay | officer: Chief Medical Officer | −370 | $65.77 |
| May 8, 2026 | Salomon Azoulay | officer: Chief Medical Officer | −70,003 | $38.36 |
| May 6, 2026 | P. Kent Hawryluk | director, officer: President & CEO | −607 | $29.54 |
| May 6, 2026 | Salomon Azoulay | officer: Chief Medical Officer | −231 | $29.54 |
| Mar 13, 2026 | P. Kent Hawryluk | director, officer: President & CEO | +18,500 | $28.41 |
- Ascendis Pharma (ADR)
Commercial PTH replacement leader in adult hypoparathyroidism
- Eli Lilly
Dominant incretin franchise with marketed obesity medicines
- Novo Nordisk (ADR)
Global GLP-1 obesity incumbent with Wegovy and amylin programs
- Amgen
Monthly obesity challenger with Phase 3 MariTide
- Viking Therapeutics
Phase 3 GLP-1/GIP obesity peer with oral and injectable plans
- AstraZeneca (ADR)
Late-stage PTH receptor agonist competitor in hypoparathyroidism
- Amylyx Pharmaceuticals
Pivotal PBH competitor with GLP-1 receptor antagonist avexitide
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| M.B.X. Biosciences | $59.44 | −4.10% | $2.95B | — | — | — | — |
| Ascendis Pharma (ADR) | $229.36 | −3.46% | $14.76B | 18.2 | 32.4 | 12.3 | +108.2% |
| Eli Lilly | $1,159.49 | −0.91% | $1.10T | 39.3 | 28.3 | 13.8 | +47.7% |
| Novo Nordisk (ADR) | $38.44 | −2.43% | $174.96B | 9.9 | 15.8 | 3.5 | +1.3% |
| Amgen | $408.45 | −0.44% | $221.41B | 25.5 | 17.4 | 5.8 | +9.7% |
| Viking Therapeutics | $39.81 | −2.54% | $4.77B | — | — | — | — |
| AstraZeneca (ADR) | $165.36 | −1.79% | $261.12B | 25.3 | 15.6 | 4.3 | +6.4% |
| Amylyx Pharmaceuticals | $31.80 | −3.64% | $3.67B | — | — | — | — |
| Median | 25.3 | 17.4 | 5.8 | +9.7% |